GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Cyclically Adjusted PB Ratio

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Cyclically Adjusted PB Ratio : 0.64 (As of Apr. 27, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Teva Pharmaceutical Industries's current share price is $13.81. Teva Pharmaceutical Industries's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $21.69. Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio for today is 0.64.

The historical rank and industry rank for Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio or its related term are showing as below:

TEVA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.22   Med: 0.63   Max: 3.11
Current: 0.62

During the past years, Teva Pharmaceutical Industries's highest Cyclically Adjusted PB Ratio was 3.11. The lowest was 0.22. And the median was 0.63.

TEVA's Cyclically Adjusted PB Ratio is ranked better than
81.3% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs TEVA: 0.62

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Teva Pharmaceutical Industries's adjusted book value per share data for the three months ended in Dec. 2023 was $6.695. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $21.69 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Teva Pharmaceutical Industries Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Cyclically Adjusted PB Ratio Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.33 0.30 0.38 0.48

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.37 0.33 0.47 0.48

Competitive Comparison of Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio falls into.



Teva Pharmaceutical Industries Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=13.81/21.69
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Teva Pharmaceutical Industries's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=6.695/129.4194*129.4194
=6.695

Current CPI (Dec. 2023) = 129.4194.

Teva Pharmaceutical Industries Quarterly Data

Book Value per Share CPI Adj_Book
201403 26.988 99.695 35.035
201406 27.564 100.560 35.475
201409 27.641 100.428 35.620
201412 27.367 99.070 35.751
201503 26.693 99.621 34.677
201506 27.104 100.684 34.840
201509 26.689 100.392 34.406
201512 29.172 99.792 37.833
201603 29.338 100.470 37.791
201606 29.026 101.688 36.942
201609 31.043 101.861 39.442
201612 29.278 101.863 37.199
201703 29.924 102.862 37.650
201706 23.990 103.349 30.042
201709 24.656 104.136 30.642
201712 13.500 104.011 16.798
201803 14.661 105.290 18.021
201806 13.927 106.317 16.953
201809 13.646 106.507 16.582
201812 13.500 105.998 16.483
201903 13.496 107.251 16.286
201906 12.933 108.070 15.488
201909 12.627 108.329 15.085
201912 12.793 108.420 15.271
202003 12.351 108.902 14.678
202006 12.641 108.767 15.041
202009 8.753 109.815 10.316
202012 9.144 109.897 10.768
202103 9.072 111.754 10.506
202106 9.361 114.631 10.569
202109 9.489 115.734 10.611
202112 9.315 117.630 10.249
202203 8.415 121.301 8.978
202206 8.137 125.017 8.424
202209 7.894 125.227 8.158
202212 7.025 125.222 7.260
202303 7.015 127.348 7.129
202306 6.293 128.729 6.327
202309 6.181 129.860 6.160
202312 6.695 129.419 6.695

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Teva Pharmaceutical Industries  (NYSE:TEVA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Teva Pharmaceutical Industries Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX